Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

September 03, 2013; 81 (10) Article

l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

Nicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, Johanna Breuer, Kerstin Göbel, Susanne Windhagen, Bruno Brochet, Patrick Vermersch, Christine Lebrun-Frenay, Anita Posevitz-Fejfár, Ruggero Capra, Luisa Imberti, Vera Straeten, Juergen Haas, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Ingrid Meinl, Kyle Niessen, Susan Goelz, Christoph Kleinschnitz, Clemens Warnke, Dorothea Buck, Ralf Gold, Bernd C. Kieseier, Sven G. Meuth, John Foley, Andrew Chan, David Brassat, Heinz Wiendl
First published August 7, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182a351fb
Nicholas Schwab
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tilman Schneider-Hohendorf
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vilmos Posevitz
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Breuer
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerstin Göbel
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Windhagen
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Brochet
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Vermersch
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Lebrun-Frenay
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Posevitz-Fejfár
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruggero Capra
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa Imberti
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Straeten
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juergen Haas
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte Wildemann
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Havla
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tania Kümpfel
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Meinl
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle Niessen
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Goelz
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Kleinschnitz
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Warnke
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorothea Buck
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf Gold
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd C. Kieseier
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven G. Meuth
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Foley
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Chan
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Brassat
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heinz Wiendl
From the Department of Neurology (N.S., T.S.-H., V.P., J.B., K.G., A.P.-F., S.G.M., H.W.), University of Münster; Department of Neurology (S.W.), Clinics Osnabrück, Germany; Department of Neurology and INSERM U1049 (B.B.), University Bordeaux; Department of Neurology (P.V.), University Lille Nord de France; Department of Neurology (C.L.-F.), University of Nice Medical Centre, France; Multiple Sclerosis Center (R.C.) and Diagnostics Department (L.I.), Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology (V.S.), Johannes-Wesling Clinic Minden; Department of Neurology (J. Haas, B.W., I.M.), Division of Molecular Neuroimmunology, University of Heidelberg; Institute of Clinical Neuroimmunology (J. Halva, T.K.), Ludwig-Maximilians-University, Munich, Germany; Elan Pharmaceuticals (K.N., S.G.), South San Francisco, CA; Department of Neurology (C.K.), University Clinic of Würzburg; Department of Neurology (C.W., B.C.K.), University of Düsseldorf; Department of Neurology (D. Buck), Technische Universität München, Munich; Department of Neurology (R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Rocky Mountain Multiple Sclerosis Clinic (J.F.), Salt Lake City, UT; and UMR1043 and Pole des Neurosciences CHU Toulouse (D. Brassat), University of Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Nicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, Johanna Breuer, Kerstin Göbel, Susanne Windhagen, Bruno Brochet, Patrick Vermersch, Christine Lebrun-Frenay, Anita Posevitz-Fejfár, Ruggero Capra, Luisa Imberti, Vera Straeten, Juergen Haas, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Ingrid Meinl, Kyle Niessen, Susan Goelz, Christoph Kleinschnitz, Clemens Warnke, Dorothea Buck, Ralf Gold, Bernd C. Kieseier, Sven G. Meuth, John Foley, Andrew Chan, David Brassat, Heinz Wiendl
Neurology Sep 2013, 81 (10) 865-871; DOI: 10.1212/WNL.0b013e3182a351fb

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
970

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.

Methods: Patients were recruited from 10 European and US cohorts. Of 289 patients with multiple sclerosis (MS), 224 had been treated with natalizumab (18–80 months), 21 received other immune-modulatory treatments, and 28 were untreated. We had access to samples from 16 natalizumab PML patients. Eight of these patients had given blood before the diagnosis of PML. We also analyzed non-natalizumab-treated patients who developed PML (n = 10) and age- and sex-matched healthy donors (n = 31). All flow cytometric assessments were done on previously cryopreserved, viable peripheral blood mononuclear cells.

Results: The percentage of l-selectin-expressing CD4+ T cells was significantly lower in patients treated long-term with natalizumab (40.2%) when compared with patients not receiving natalizumab treatment (47.2%; p = 0.016) or healthy controls (61.0%; p < 0.0001). An unusually low percentage (9-fold lower; 4.6%) was highly correlated with the risk of developing PML in the patient group with available pre-PML samples when compared with non-PML natalizumab-treated patients (p ≤ 0.0001). Samples were gathered between 4 and 26 months before PML diagnosis.

Conclusions: The cell-based assessment of the percentage of l-selectin-expressing CD4 T cells could provide an urgently needed biomarker for individual PML risk assessment.

GLOSSARY

EDTA=
ethylenediaminetetraacetic acid;
JCV=
JC virus;
PBMC=
peripheral blood mononuclear cells;
PML=
progressive multifocal leukoencephalopathy;
RRMS=
relapsing-remitting multiple sclerosis

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at www.neurology.org

  • Editorial, page 858

  • Received January 6, 2013.
  • Accepted in final form April 24, 2013.
  • © 2013 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • Risk factors for rare diseases can be risky to definePML and natalizumab

Topics Discussed

  • Multiple sclerosis
  • Diagnostic test assessment
  • Prognosis
  • Patient safety
  • Viral infections

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise